Zhou A G, Huang D W, Ding Y X, Jiang H, Tang M L
A-Gao Zhou, Yu-Xiong Ding, Ming-Lin Tang, Department of Traditional Chinese Medicine, Shanghai Second Medical University, Shanghai 200025, China.
World J Gastroenterol. 1997 Sep 15;3(3):189-91. doi: 10.3748/wjg.v3.i3.189.
To study effects of the Fuzheng Huoxue anticancer prescription (Traditional Chinese Medicine) in treatment of gastric cancer.
Sixty-nine patients with histologically confirmed mid- or late-stage gastric cancer were assigned to two groups. The treatment group included 35 cases (26 males and 9 females; 2 patients aged 33-40 years, 18 patients aged 41-60 years, and 15 patients aged 61-75 years; mean group age = 58.4 years). The control group included 34 cases (23 males and 11 females; 4 patients aged 33-40 years, 16 patients aged 41-60 years, and 14 patients aged 61-75 years; mean group age = 56.8 years. The two groups were not significantly different in sex, age, their clinical and pathological stages of disease or operation mode. The two groups of patients were given similar treatments; however, patients in the treatment group were given the Fuzheng Huoxue anticancer prescription. In animal studies, SGC-7901 gastric cancers cells were inoculated into the backs of 30 nude mice under sterile conditions. After inoculation, the nude mice were randomly allocated to a control group, a traditional Chinese medicine group, and a chemotherapy group (n = 10 mice per group). The total weight of the 10 mice in each group was similar. Each nude mouse in the control group received 0.5 mL of saline solution each day. Mice in the traditional Chinese medicine group received 0.5 mL of the Fuzheng Huoxue anticancer prescription (containing 1.5 g crude drug) each day, while mice in the chemotherapy group were intraperitoneally injected with 1 mg of 5-Fu once a week for 8 wk.
Prior to treatment, the mean OKT8 percentage among gastric patients in the treatment group was 45.94% ± 8.45%, the mean OKT4/OKT8 ratio was 0.89 ± 0.19, the mean AT-III concentration was 29.9 ± 7.9 mg/dL, the mean Fa value was 50.4% ± 24.4%, and the mean β-TG concentration was 91.0 ± 25.9 ng/dL. Prior to treatment, the mean percentage of OKT8 cells among patients in the control group was 49.21% ± 6.60%, the OKT4/OKT8 ratio was 0.94 ± 0.20, the AT-III concentration was 32.3 ± 7.2 mg/dL, the mean Fa value was 57.3% ± 24.6%, and the mean β-TG concentration was 87.5 ± 34.2 ng/dL. After treatment, the mean OKT8 percentage among patients in the treatment group was 33.52% ± 7.80%, the mean OKT4/OKT8 ratio was 1.47 ± 0.51, the mean AT-III concentration was 38.8 ± 5.5 mg/dL, the mean Fa value was 102.6% ± 31.6%, and the mean β-TG concentration was 62.3 ± 15.1 ng/dL. After treatment, the mean OKT8 percentage among patients in the control group was 42.22% ± 7.07%, the mean OKT4/OKT8 ratio was 1.12 ± 0.24, the mean AT-III concentration was 30.9 ± 8.0 mg/dL, the mean Fa value was 64.6% ± 26.9%, and the mean β-TG concentration was 67.0 ± 42.1 ng/dL. These data indicate that after treatment, the immunologic function of the T lymphocytes of gastric cancer patients in the treatment group was significantly improved (P < 0.01). Additionally, the hypercoagulability in the treatment group was also improved (P < 0.001), and the mean OKT4/OKT8 ratio, antithrombin III (AT-III) concentration, and fibrinolytic activity, etc. had all beome normalized. The one-year (86%), 3-year (69%), and 5-year (40%) survival rates in the treatment group were all higher than those in the control group (P < 0.05). The mean tumor weights in the control, traditional medicine, and chemotherapy groups were 0.895 ± 0.289 g, 0.433 ± 0.177 g, and 0.357 ± 0.142 g, respectively. The tumor-inhibition rates in the traditional Chinese medicine group and chemotherapeutic group (51.6% and 60.1%, respectively) were significantly better than that in the control group (P < 0.001). The mean tumor weight in the traditional Chinese medicine group (24.68 ± 1.93 g) was significantly higher than that in both the treatment group (22.96 ± 1.87 g) and control group (22.47 ± 2.18 g).
The Fuzheng Huoxue anticancer prescription can not only replenish vital functions (Zhengqi), correct a hypercoagulatory state, improve immunologic function, and extend patient survival times, but may also directly inhibit gastric tumor growth without producing toxic side effects.
研究扶正活血抗癌方（中药）治疗胃癌的效果。
69例经组织学确诊的中晚期胃癌患者被分为两组。治疗组35例（男26例，女9例；年龄33 - 40岁2例，41 - 60岁18例，61 - 75岁15例；组平均年龄 = 58.4岁）。对照组34例（男23例，女11例；年龄33 - 40岁4例，41 - 60岁16例，61 - 75岁14例；组平均年龄 = 56.8岁。两组在性别、年龄、疾病临床和病理分期或手术方式方面无显著差异。两组患者接受相似的治疗；然而，治疗组患者给予扶正活血抗癌方。在动物研究中，将SGC - 7901胃癌细胞在无菌条件下接种到30只裸鼠的背部。接种后，将裸鼠随机分为对照组、中药组和化疗组（每组10只小鼠）。每组10只小鼠的总重量相似。对照组的每只裸鼠每天接受0.5 mL生理盐水。中药组的小鼠每天接受0.5 mL扶正活血抗癌方（含1.5 g生药），而化疗组的小鼠每周腹腔注射1 mg 5 - 氟尿嘧啶，共8周。
治疗前，治疗组胃癌患者的平均OKT8百分比为45.94% ± 8.45%，平均OKT4/OKT8比值为0.89 ± 0.19，平均抗凝血酶III（AT - III）浓度为29.9 ± 7.9 mg/dL，平均纤维蛋白原降解产物（Fa）值为50.4% ± 24.4%，平均β - 血小板球蛋白（β - TG）浓度为91.0 ± 25.9 ng/dL。治疗前，对照组患者的平均OKT8细胞百分比为49.21% ± 6.60%，OKT4/OKT8比值为0.94 ± 0.20，AT - III浓度为32.3 ± 7.2 mg/dL，平均Fa值为57.3% ± 24.6%，平均β - TG浓度为87.5 ± 34.2 ng/dL。治疗后，治疗组患者的平均OKT8百分比为33.52% ± 7.80%，平均OKT4/OKT8比值为1.47 ± 0.51，平均AT - III浓度为38.8 ± 5.5 mg/dL，平均Fa值为102.6% ± 31.6%，平均β - TG浓度为62.3 ± 15.1 ng/dL。治疗后，对照组患者的平均OKT8百分比为42.22% ± 7.07%，平均OKT4/OKT8比值为1.12 ± 0.24，平均AT - III浓度为30.9 ± 8.0 mg/dL，平均Fa值为64.6% ± 26.9%，平均β - TG浓度为67.0 ± 42.1 ng/dL。这些数据表明，治疗后，治疗组胃癌患者的T淋巴细胞免疫功能显著改善（P < 0.01）。此外，治疗组的高凝状态也得到改善（P < 0.001），平均OKT4/OKT8比值、抗凝血酶III（AT - III）浓度和纤溶活性等均已恢复正常。治疗组的1年（86%）、3年（69%）和5年（40%）生存率均高于对照组（P < 0.05）。对照组、中药组和化疗组的平均肿瘤重量分别为0.895 ± 0.289 g、0.433 ± 0.177 g和0.357 ± 0.142 g。中药组和化疗组的肿瘤抑制率（分别为51.6%和60.1%）显著优于对照组（P < 0.001）。中药组的平均肿瘤重量（24.68 ± 1.93 g）显著高于治疗组（22.96 ± 1.87 g）和对照组（22.47 ± 2.18 g）。
扶正活血抗癌方不仅能扶正固本、纠正高凝状态、改善免疫功能、延长患者生存时间，还可能直接抑制胃肿瘤生长而不产生毒副作用。
